Clinical Trial Update: Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder [NA]

View source ↗

Summary

A completed clinical trial from Xijing Hospital evaluated fluoxetine for refractory Superior Mesenteric Artery Syndrome with comorbid Somatic Symptom Disorder, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Somatic Symptom Disorder
• Superior Mesenteric Artery Syndrome

Drugs mentioned

• Fluoxetine (Fluoxetine)

Snippet

Sponsor: Xijing Hospital of Digestive Diseases | Conditions: Superior Mesenteric Artery Syndrome, Somatic Symptom Disorder (DSM-5) | NA | Status: COMPLETED